Quantbot Technologies LP Purchases Shares of 61,136 Oscar Health, Inc. (NYSE:OSCR)

Quantbot Technologies LP bought a new stake in Oscar Health, Inc. (NYSE:OSCR - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 61,136 shares of the company's stock, valued at approximately $1,297,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in shares of Oscar Health by 31.7% during the second quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company's stock worth $61,478,000 after purchasing an additional 934,600 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Oscar Health by 32.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,046,046 shares of the company's stock worth $32,368,000 after acquiring an additional 507,009 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Oscar Health by 20.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,600,166 shares of the company's stock valued at $33,940,000 after acquiring an additional 270,223 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Oscar Health by 161.4% during the second quarter. Bank of New York Mellon Corp now owns 1,393,048 shares of the company's stock valued at $22,038,000 after acquiring an additional 860,226 shares during the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Oscar Health during the third quarter worth $27,452,000. Institutional investors and hedge funds own 75.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on OSCR. Piper Sandler restated an "overweight" rating and issued a $28.00 price objective on shares of Oscar Health in a report on Tuesday, September 10th. UBS Group initiated coverage on Oscar Health in a research report on Monday, October 7th. They issued a "neutral" rating and a $23.00 price target on the stock. Finally, Bank of America downgraded Oscar Health from a "neutral" rating to an "underperform" rating and lowered their price objective for the stock from $21.00 to $13.50 in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $22.93.

Oscar Health Trading Up 3.0 %

Shares of OSCR stock traded up $0.50 during mid-day trading on Friday, hitting $17.33. The company's stock had a trading volume of 1,167,094 shares, compared to its average volume of 5,480,658. The company has a market cap of $4.29 billion, a PE ratio of -288.79 and a beta of 1.67. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73. The company's fifty day simple moving average is $17.33 and its 200-day simple moving average is $17.99. Oscar Health, Inc. has a 52 week low of $7.29 and a 52 week high of $23.79.

Oscar Health (NYSE:OSCR - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same period in the prior year, the business earned ($0.29) EPS. The company's revenue for the quarter was up 68.3% on a year-over-year basis. As a group, equities research analysts expect that Oscar Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mario Schlosser sold 3,198 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $17.99, for a total transaction of $57,532.02. Following the completion of the sale, the insider now owns 76,982 shares in the company, valued at $1,384,906.18. The trade was a 3.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Thrive Partners Vii Growth Gp, bought 420,819 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $13.68 per share, for a total transaction of $5,756,803.92. Following the completion of the transaction, the director now directly owns 5,452,081 shares of the company's stock, valued at $74,584,468.08. This trade represents a 8.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 1,055,478 shares of company stock worth $14,432,852 and sold 194,569 shares worth $3,433,319. 25.11% of the stock is currently owned by company insiders.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.